Physician profile
Robert A Feldman
NPI 1184620627
$552.31
in general payments reported to CMS, 2019-2025
13 companies · $77.70 in 2025
The $77.70 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $25.79 · 2023: $117 · 2024: $88.86 · 2025: $77.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $283.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $118.36 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $104.57 | 2019-2024 | |
| Abbvie INC. | $56.47 | 2023 | |
| Janssen Biotech, INC. | $47.47 | 2019 | |
| Novo Nordisk INC | $42.34 | 2023-2024 | |
| Glaxosmithkline, LLC. | $40.36 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $27.80 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $24.91 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.30 | 2019 | |
| Lilly USA, LLC | $23.27 | 2025 | Mounjaro |
| Inspire Medical Systems, INC. | $16.74 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $14.04 | 2019 | |
| Merck Sharp & Dohme LLC | $11.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.